Nature Medicine commentary: KRAS G12D inhibitors show encouraging activity in phase 1 studies

This Nature Medicine commentary discusses two early-phase clinical trials of selective KRAS G12D inhibitors, which reported encouraging antitumor activity in patients with advanced cancers carrying the G12D mutation — one of the most common and historically undruggable oncogenic drivers. The author argues the results extend RAS-targeted treatment beyond the earlier KRAS G12C class, with potential relevance across pancreatic, colorectal and lung cancers. It is an editorial commentary, not a trial readout: the underlying data come from phase 1 studies and no survival benefit has been demonstrated.